R&D progress and launch time of the domestic targeted drug Sotorasib (AMG 510) (Sotorasib)

Sotoracib (AMG 510) is the world's first approved KRAS G12C inhibitor and is mainly used to treat patients with non-small cell lung cancer harboring KRAS G12C mutations. The emergence of this drug breaks the deadlock that KRAS mutations are "undruggable" and brings new hope to some patients who lacked effective treatment options in the past. In international clinical trials, sotorasiib has shown relatively ideal objective response rates and disease control rates, and has therefore become a research hotspot in the field of cancer targeted therapy in recent years.

Currently, sotoraxibu has not been officially launched in China, and the research and development of the domestic version is still in progress. According to public information in the industry, many domestic pharmaceutical companies have begun the development of KRAS G12C targeted drugs, and some have entered the clinical trial stage, but it will still take some time before they are actually approved for marketing. This means that in the short term, domestic patients will still not be able to obtain sotorasibu directly through regular hospital channels and will need to rely on overseas drugs as an alternative.

In overseas markets, the original drug of sotorasibu has European and Hong Kong versions. The price is generally expensive, ranging from tens of thousands to tens of thousands of yuan, which puts great financial pressure on patients. In contrast, generic drugs that have appeared overseas are more affordable. Especially in the Laotian market, generic drug companies (such as Lucius and Daxiong) have launched generic versions of sotorasibu, and the price has been significantly reduced recently. Taking 120mg×56 tablets as an example, the price is only more than 1,000 yuan, which is a huge gap compared to the original drug.

Currently, if domestic patients have urgent needs, they can obtain the original drug or generic drug of sotorasibu through regular overseas channels, but they must pay attention to the legality and quality assurance of the drug source. Use medication under the guidance of a doctor to ensure safety and efficacy. At the same time, with the advancement of domestic research and development, domestic sotorasibu or similar KRAS G12C inhibitors are expected to be launched in the next few years. By then, the price may be more affordable and patients' medication options will be more diverse. It is foreseeable that with the gradual popularization of generic drugs and domestic drugs, the dual financial and treatment pressures on patients will be significantly alleviated.

Reference link:https://www.drugs.com